Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

by Pobiner Bonnie F, Liao Qiming, Tashima Karen T, Berger Daniel S, Cohen Calvin J, Swindells Susan, Snidow Jerry W, Pakes Gary E, Hernandez Jaime E
Published 2005-04-01

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

by Griffith Sandy, Liao Qiming, Richmond Gary J, Pollard Richard B, Gathe Joseph C, Nadler Jeffrey P, Tracey Lancaster C, Hernandez Jaime E, Pappa Keith A
Published 2003-06-01

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

by Snidow Jerry W, Wakeford John H, Williams Vanessa C, Olliffe Jeffrey F, Rodriguez Allan, DeJesus Edwin, Sension Michael G, Keiser Philip H, Shachoy-Clark Anne D, Fleming Julie W, Pakes Gary E, Hernandez Jaime E
Published 2005-01-01